Oral Probiotics for Halitosis in Healthy Adults

ConditionHalitosis

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-70

SponsorJohn Hale

About this trial

The aim of this study is to evaluate efficacy of a probiotic lozenge containing BLIS M18, BLIS K12 and a prebiotic in healthy adults.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participants should be otherwise healthy,

practice good oral hygiene,

18 - 70 years of age

Disqualifiers

on antibiotic therapy,

immunocompromised (have a weakened immune system)

history of autoimmune disease,

allergy or sensitivity to dairy,

Trial design

Design model

Parallel

Treatments tested in this trial

In this study, a probiotic lozenge formulation containing S. salivarius K12, M18 and prebiotic will be evaluated for its potential to improve bad breath
Dietary supplement
In this study, a probiotic-free lozenge formulation containing S. salivarius K12, M18 and prebiotic will be evaluated for its potential to improve bad breath as a comparator.
Placebo
Other intervention
Probiotic free placebo lozenge

Treatment groups

40 Participants

are divided into 2 treatment groups

Group A: Oral probiotic lozengesActive comparator 1 intervention

Group B: Placebo lozengesPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Measurement of Volatile Sulphur Compounds in ppb between the active and placebo groups

Study will determine the change in Volatile Sulphur Compounds (VSCs) as measured in ppb, following application of probiotic lozenges containing Streptococcus salivarius K12, Streptococcus salivarius M18 and prebiotic compared with a placebo lozenge. Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to post cysteine mouthrinse before the lozenge application and 13 days after once a day lozenge application with the level of significance of p≤0.05 across the probiotic and placebo lozenge. Appropriate statistical analysis software (e.g. Microsoft Excel) will be used to analyse the data

Time frame

13 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

John Hale

Lead sponsor

BLIS Technologies Limited

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: